True North Therapeutics, Inc.

Gilead Biologics, Inc.

Bioverativ USA Inc.

Armo Biosciences, Inc.

Peter Van Vlasselaer

Nancy E Stagliano

Graham Parry

Sandip Panicker

Victoria Smith

Scott Alan McCauley

Hector Rodriguez

Derek Marshall

Alison Kay Holzer

Scott Ogg

Carlos Aurelio Garcia

Donna Hiroko Tokuoka Biermann

Miho Oyasu

Vivian E Barry

John Brian Mumm

Scott Alan Mccauley

Donna Hiroko Biermann

The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Anti-complement C1s antibodies and uses thereof

The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.

LOX and LOXL2 inhibitors and uses thereof

Anti-complement C1s antibodies

The present invention relates to methods and other technologies that may be used to determine whether compositions (e.g., pharmaceutical compositions) comprising interleukin-10 molecules (e.g., pegylated interleukin-10) meet particular product-related specifications prior to being administered to a subject for the treatment and/or prevention of the diseases, disorders and conditions, and/or the symptoms thereof, described herein.

Method for assessing protein identity and stability

Anti-complement C1s antibodies and methods of inhibiting complement C1s activity

The present disclosure provides antibodies that bind complement Cs protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Methods of inhibiting complement C4 activation with anti-complement C1s antibodies

Methods of inhibiting complement C4 activation with anti-complement C1S antibodies

Methods of inhibiting activation of complement component C4 with anti-C1s antibodies

Growing community of inventors

Portola Valley, CA, United States of America

Peter Van Vlasselaer